All In Biotech

Drug Trial Radar · NCT06259422

Method VALIDation and Evaluation of Non-radioactive Methods to Measure Glomerular Filtration Rate

Last checked: Nov 20, 2026Latest source record: Mar 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

208

Planned (sponsor's estimate)

Start

Jun 1, 2024

Primary completion

Sep 1, 2025

Study completion Sep 1, 2025

Sponsor

Lead sponsor
University Medical Center GroningenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 14, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a single centre intervention study to compare two methods of determining the measured glomerular filtration rate (mGFR). Subjects who receive radioactively labeled iothalamate (125I) and hippuran (131I) within the framework of routine clinical care, will be co-administered iohexol. The primary trial endpoint is the mGFR when administered 125I-iothalamate and 131I-hippuran versus iohexol. By determining the mGFR using both iohexol and iothalamate in the same patients, a direct comparison of the two methods can be made in terms of their accuracy and precision. This makes it possible to determine the potential use of the non-radioactive measurement method as an alternative to the radioactive method and thus lower the overall radioactive burden for patients and personnel.

Conditions

  • Kidney Function Issue
  • Diagnosis
  • Chronic Kidney Diseases

Interventions

  • IohexolDrug

    Subjects will receive a single bolus of 5 mL of Omnipaque 300 (containing 3235 mg iohexol)

  • 125I-iothalamate and 131I-hippuranDiagnostic test

    Subjects will receive 125I-iothalamate and 131I-hippuran as part of their routine clinical care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. mGFR IohexolTime frame: Through study completion, an average of 1 year
  2. mGFR Iothalamate and hippuranTime frame: Through study completion, an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Medical Centre Groningen

    Groningen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.